03/08/2010
EUSA Pharma completes establishment of commercial infrastructure with appointment of President for Europe and International region
Oxford, UK and Langhorne, PA, USA – 8 March 2010
EUSA Pharma (‘EUSA’), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the appointment of Iain McGill to the role of President, Europe and International. The appointment marks the completion of the build of both EUSA’s executive management team and the company’s commercial infrastructure. With EUSA now present in over 80 countries, with teams covering the US and over 20 European territories including the major EU markets, the company anticipates achieving strong sales growth and profitability in 2010.
Mr McGill joins EUSA from Wyeth Pharmaceuticals, where he held the position of Vice President and Global Manager for the company’s transplantation business. Previously, he was the Head of Novartis’ Transplantation, Immunology and Infectious Diseases Business Unit in Canada, and was a Global Brand Director at Novartis’ headquarters in Switzerland. He also held a number of sales and marketing positions of increasing seniority at Novartis and Roche in the UK. Mr McGill holds a BSc in Biochemistry from Royal Holloway College, London University.
“We are delighted to welcome Iain to EUSA at such an exciting time in the company’s development,” said Bryan Morton, EUSA Pharma’s President and Chief Executive Officer. “Since founding EUSA four years ago, we have made tremendous progress, raising over $300 million in investment funding, establishing a portfolio of eight marketed and four pipeline products, and building a strong commercialization platform on both sides of the Atlantic. Iain’s leadership skills, and track record of growing specialist pharmaceutical businesses, will prove invaluable as we complete EUSA’s transition from a development-stage company to a world leader in its field.”
Commenting on his appointment, Iain McGill, EUSA Pharma’s President, Europe and International, said, “Having seen the team at EUSA build a great company in a very short period of time, I am delighted to join them as we drive the business to the next level. With an infrastructure now in place that can rival even our biggest competitors, EUSA is well positioned to continue its rapid development. I welcome the opportunity to contribute to that progress, as we focus on aggressive organic growth and further product in-licensing and acquisition.”
